Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP. Cardoso F, et al. Among authors: neciosup s. Ann Oncol. 2020 Dec;31(12):1623-1649. doi: 10.1016/j.annonc.2020.09.010. Epub 2020 Sep 23. Ann Oncol. 2020. PMID: 32979513 Free PMC article. No abstract available.
Impact on Survival with Immunotherapy and Evaluation of Biomarkers in Peruvian Patients with Advanced Melanoma.
Valencia G, Roque K, Rioja P, Huamán JA, Colomo V, Sánchez J, Calle C, Mantilla R, Morante Z, Fuentes H, Vidaurre T, Neciosup S, De Mello RA, Gómez HL, Fernández-Díaz AB, Berrocal A, Castaneda C. Valencia G, et al. Among authors: neciosup s. Onco Targets Ther. 2024 Nov 2;17:871-886. doi: 10.2147/OTT.S483753. eCollection 2024. Onco Targets Ther. 2024. PMID: 39507408 Free PMC article.
Subpopulation treatment effect pattern plot analysis: a prognostic model for distant recurrence-free survival to estimate delayed adjuvant chemotherapy initiation effect in triple-negative breast cancer.
Morante Z, Ferreyra Y, Pinto JA, Valdivieso N, Castañeda C, Vidaurre T, Valencia G, Rioja P, Fuentes H, Cotrina JM, Neciosup S, Gomez HL. Morante Z, et al. Among authors: neciosup s. Front Oncol. 2023 Nov 6;13:1193927. doi: 10.3389/fonc.2023.1193927. eCollection 2023. Front Oncol. 2023. PMID: 38023174 Free PMC article.
Genomic Landscape in Prostate Cancer in a Latin American Population.
Angel M, Freile B, Rodriguez A, Cayol F, Manneh Kopp R, Rioja P, Soule T, Losco F, Bernal Vaca L, Penaloza JM, Zapata Muñoz ML, Neciosup SP, Sanchez RR, Passarella C, Guerreño E, Farelluk D, Maturana Leiva E, Zarba M, Bourlon MT, Mora Pineda M, Sade JP. Angel M, et al. Among authors: neciosup sp. JCO Glob Oncol. 2024 Sep;10:e2400072. doi: 10.1200/GO.24.00072. Epub 2024 Sep 30. JCO Glob Oncol. 2024. PMID: 39348607
Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer.
Otoya I, Valdiviezo N, Morante Z, Calle C, Ferreyra Y, Huarcaya-Chombo N, Polo-Mendoza G, Castañeda C, Vidaurre T, Neciosup SP, Calderón MJ, Gomez HL. Otoya I, et al. Among authors: neciosup sp. Int J Breast Cancer. 2024 Jun 22;2024:9551710. doi: 10.1155/2024/9551710. eCollection 2024. Int J Breast Cancer. 2024. PMID: 38962673 Free PMC article.
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group. Gligorov J, et al. Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16. Eur J Cancer. 2017. PMID: 28625777 Clinical Trial.
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group. André F, et al. N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904. N Engl J Med. 2019. PMID: 31091374 Clinical Trial.
41 results